Jazz Pharmaceuticals PLC (JAZZ)
103.53
-1.56
(-1.48%)
USD |
NASDAQ |
Jul 03, 16:00
Jazz Pharmaceuticals Research and Development Expense (Annual): 849.66M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 849.66M |
| December 31, 2022 | 590.45M |
| December 31, 2021 | 505.75M |
| December 31, 2020 | 335.38M |
| December 31, 2019 | 299.73M |
| December 31, 2018 | 226.62M |
| December 31, 2017 | 198.44M |
| December 31, 2016 | 162.30M |
| December 31, 2015 | 135.25M |
| December 31, 2014 | 85.18M |
| Date | Value |
|---|---|
| December 31, 2013 | 41.63M |
| December 31, 2012 | 20.48M |
| December 31, 2011 | 14.12M |
| December 31, 2010 | 25.61M |
| December 31, 2009 | 36.56M |
| December 31, 2008 | 69.96M |
| December 31, 2007 | 69.79M |
| December 31, 2006 | 54.96M |
| December 31, 2005 | 45.78M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
299.73M
Minimum
2019
849.66M
Maximum
2023
516.19M
Average
505.75M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Medtronic PLC | 2.735B |
| Alkermes PLC | 270.81M |
| Perrigo Co PLC | 122.50M |
| Trinity Biotech PLC | 4.379M |
| Iterum Therapeutics PLC | 39.99M |